ArticleInternational journal of antimicrobial agents2020
SARS-CoV-2: fear versus data.
Article in International journal of antimicrobial agents, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04705766 (The KIDCOV Study), which is not on this map. Cited by 31 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
The KIDCOV Study: ASSESSMENT of SARS-CoV-2 Without HOSPITALIZATION as a RISK FACTOR for ACUTE KIDNEY INJURY
Who cites it
31 citing papers in PubMed.
- From zoonotic spillover to endemicity: the broad determinants of human coronavirus tropism.mBio · 2025Review
- 'Spikeopathy': COVID-19 Spike Protein Is Pathogenic, from Both Virus and Vaccine mRNA.Biomedicines · 2023Review
- Article
- Immune responses in mildly versus critically ill COVID-19 patients.Frontiers in immunology · 2023Review
- SARS-CoV-2 variant identification using a genome tiling array and genotyping probes.Personalized medicine · 2023Article
- Cohort study protocol of the Brazilian collaborative research network on COVID-19: strengthening WHO global data.BMJ open · 2022Article
- Molecular docking, DFT analysis, and dynamics simulation of natural bioactive compounds targeting ACE2 and TMPRSS2 dual binding sites of spike protein of SARS CoV-2.Journal of molecular liquids · 2021Article
- Live Imaging and Quantification of Viral Infection in K18 hACE2 Transgenic Mice Using Reporter-Expressing Recombinant SARS-CoV-2.Journal of visualized experiments : JoVE · 2021Article
- Virtual screening, ADMET prediction and dynamics simulation of potential compounds targeting the main protease of SARS-CoV-2.Journal of biomolecular structure & dynamics · 2021Article
- Feline infectious peritonitis (FIP) and coronavirus disease 19 (COVID-19): Are they similar?Transboundary and emerging diseases · 2021Review
- Article
- Stroke Patients' Characteristics and Clinical Outcomes: A Pre-Post COVID-19 Comparison Study.Medicina (Kaunas, Lithuania) · 2021Article
- COVIDOUTCOME-estimating COVID severity based on mutation signatures in the SARS-CoV-2 genome.Database : the journal of biological databases and curation · 2021Article
- An integrative look at SARS‑CoV‑2 (Review).International journal of molecular medicine · 2021Review
- Different mutations in SARS-CoV-2 associate with severe and mild outcome.International journal of antimicrobial agents · 2021Article
- Adaptation and psychometric evaluation of Hungarian version of the Fear of COVID-19 Scale.PloS one · 2021Article
- Understanding the andromeda strain - The role of cytokine release, coagulopathy and antithrombin III in SARS-CoV2 critical illness.Blood reviews · 2021Review
- Narrative review of the novel coronavirus SARS-CoV-2: update on genomic characteristics, transmissions and animal model.Journal of thoracic disease · 2020Review
- SARS-CoV-2 and Dentistry-Review.European journal of dentistry · 2020Article
- Comparing and Contrasting MERS, SARS-CoV, and SARS-CoV-2: Prevention, Transmission, Management, and Vaccine Development.Pathogens (Basel, Switzerland) · 2020Review
Corrections and comments
- Commented on by
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
SARS-CoV-2, the novel coronavirus from China, is spreading around the world, causing a huge reaction despite its current low incidence outside China and the Far East. Four common coronaviruses are in current circulation and cause millions of cases worldwide. This article compares the incidence and mortality rates of these four common coronaviruses with those of SARS-CoV-2 in Organisation for Economic Co-operation and Development countries. It is concluded that the problem of SARS-CoV-2 is probably being overestimated, as 2.6 million people die of respiratory infections each year compared with less than 4000 deaths for SARS-CoV-2 at the time of writing.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.